Results of multivariate models of time to GVHD, time to treatment-related mortality, and overall survival using continuous day 7 TNFR1 ratio
| Variable . | Category . | GVHD . | TRM . | OS . | |||
|---|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | ||
| Day 7 TNFR1 ratio | 1.14 | <0.001 | 1.17 | <0.001 | 1.08 | .02 | |
| Donor type | MRD | Ref | — | Ref | — | Ref | — |
| MUD | 1.90 | <0.001 | 3.37 | <0.001 | 1.50 | .006 | |
| Match | Yes | Ref | — | Ref | — | Ref | — |
| No | 1.99 | 0.005 | 1.07 | 0.83 | 1.24 | .29 | |
| Recipient age* | 1.05 | 0.39 | 1.29 | <0.001 | 1.11 | .03 | |
| Donor → recipient | Male → male | Ref | — | Ref | — | Ref | — |
| Female → male | 1.20 | 0.34 | 1.21 | 0.48 | 1.03 | .87 | |
| Sex | Male → female | 0.62 | 0.03 | 0.71 | 0.23 | 0.89 | .54 |
| Female → female | 0.85 | 0.67 | 0.79 | 0.62 | 1.00 | >.99 | |
| Diagnosis and disease status | Nonmalignant | Ref | — | Ref | — | Ref | — |
| Standard risk | 1.70 | 0.32 | 0.94 | 0.93 | 4.17 | .05 | |
| Advanced risk | 1.66 | 0.35 | 1.25 | 0.74 | 7.42 | .006 | |
| Preparative regimen | Non-TBI | Ref | — | Ref | — | Ref | — |
| TBI | 1.08 | 0.80 | 0.63 | 0.23 | 1.19 | .42 | |
| Variable . | Category . | GVHD . | TRM . | OS . | |||
|---|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | ||
| Day 7 TNFR1 ratio | 1.14 | <0.001 | 1.17 | <0.001 | 1.08 | .02 | |
| Donor type | MRD | Ref | — | Ref | — | Ref | — |
| MUD | 1.90 | <0.001 | 3.37 | <0.001 | 1.50 | .006 | |
| Match | Yes | Ref | — | Ref | — | Ref | — |
| No | 1.99 | 0.005 | 1.07 | 0.83 | 1.24 | .29 | |
| Recipient age* | 1.05 | 0.39 | 1.29 | <0.001 | 1.11 | .03 | |
| Donor → recipient | Male → male | Ref | — | Ref | — | Ref | — |
| Female → male | 1.20 | 0.34 | 1.21 | 0.48 | 1.03 | .87 | |
| Sex | Male → female | 0.62 | 0.03 | 0.71 | 0.23 | 0.89 | .54 |
| Female → female | 0.85 | 0.67 | 0.79 | 0.62 | 1.00 | >.99 | |
| Diagnosis and disease status | Nonmalignant | Ref | — | Ref | — | Ref | — |
| Standard risk | 1.70 | 0.32 | 0.94 | 0.93 | 4.17 | .05 | |
| Advanced risk | 1.66 | 0.35 | 1.25 | 0.74 | 7.42 | .006 | |
| Preparative regimen | Non-TBI | Ref | — | Ref | — | Ref | — |
| TBI | 1.08 | 0.80 | 0.63 | 0.23 | 1.19 | .42 | |
GVHD indicates graft-versus-host disease; TRM, treatment-related mortality; OS, overall survival; HR, hazard ratio; TNFR1; TNF receptor 1; Ref, reference group; —, not applicable; MRD, matched related donor; MUD, matched unrelated donor; Standard risk, lymphoma with chemosensitive disease, leukemia in complete remission (ie, CR1, CR2, or CR3), or untreated myelodysplastic syndrome at the time of transplantation; Advanced risk, leukemia not in remission, or lymphoma with stable or progressive disease at the time of transplantation; and TBI, total body irradiation.
For recipient age, the HR reflects the change in hazard for every 10 years.